Symptomatic, culture‐verified UTI Women with recurrent UTI · preventing UTI
Any cranberry product probably leads to lower symptomatic, culture‐verified UTI Women with recurrent UTI compared with placebo or control (moderate certainty).
1 finding from 1 review
Symptomatic, culture‐verified UTI Elderly men and women in institutions · preventing UTI
Any cranberry product showed no clear difference in symptomatic, culture‐verified UTI Elderly men and women in… compared with placebo or control (moderate certainty).
1 finding from 1 review
Symptomatic, culture‐verified UTI Children · preventing UTI
Any cranberry product probably leads to lower symptomatic, culture‐verified UTI Children compared with placebo or control (moderate certainty).
1 finding from 1 review
Symptomatic, culture‐verified UTI Adults with bladder emptying issues or multiple sclerosis · preventing UTI
Any cranberry product showed no clear difference in symptomatic, culture‐verified UTI Adults with bladder emptying… compared with placebo or control (low certainty).
1 finding from 1 review
Symptomatic, culture‐verified UTI People with a susceptibility to a UTI due to an intervention · preventing UTI
Any cranberry product may leads to lower symptomatic, culture‐verified UTI People with a susceptibility to a… compared with placebo or control (low certainty).
1 finding from 1 review
Gastrointestinal adverse events · preventing UTI
Any cranberry product showed no clear difference in gastrointestinal adverse events compared with placebo or control (moderate certainty).
1 finding from 1 review
IVH any grade (Papile classification) during hospitalisation · preterm infants with or at risk of IVH
Phenobarbital showed no clear difference in IVH any grade (Papile classification) during hospitalisation compared with control (low certainty).
1 finding from 1 review
Severe intraventricular haemorrhage · preterm infants with or at risk of IVH
Phenobarbital showed no clear difference in severe IVH (Papile classification) during hospitalisation compared with control (low certainty).
1 finding from 1 review
Ventricular dilation or hydrocephalus during hospitalisation · preterm infants with or at risk of IVH
It is very uncertain whether phenobarbital changes ventricular dilation or hydrocephalus during hospitalisation compared with control (very low certainty).
1 finding from 1 review
Mild neurodevelopmental impairment at 27 months of age · preterm infants with or at risk of IVH
It is very uncertain whether phenobarbital changes mild neurodevelopmental impairment at 27 months of age compared with control (very low certainty).
1 finding from 1 review
Severe neurodevelopmental impairment at 9 to 27 months of age · preterm infants with or at risk of IVH
It is very uncertain whether phenobarbital changes severe neurodevelopmental impairment at 9 to 27 months of age compared with control (very low certainty).
1 finding from 1 review
Mortality before hospital discharge · preterm infants with or at risk of IVH
Phenobarbital showed no clear difference in death before discharge compared with control (low certainty).
1 finding from 1 review
All deaths during the study · preterm infants with or at risk of IVH
Phenobarbital showed no clear difference in all deaths during the study compared with control (low certainty).
1 finding from 1 review
Adverse events: death ‐ at end of treatment (secondary outcome) · people with depression after stroke
1 finding from 1 review
Adverse effects (central nervous system) · people with depression after stroke
Non‐invasive brain stimulation showed no clear difference in adverse events: all ‐ central nervous system events (e.g. confusion,… compared with sham non‐invasive brain stimulation and/or usual care (low certainty).
1 finding from 1 review
Adverse events: all ‐ other events ‐ not listed above (e.g. dysuria, neck pain, eye discomfort) (secondary outcome) · people with depression after stroke
Non‐invasive brain stimulation showed no clear difference in adverse events: all ‐ other events ‐ not listed above (e.g. dysuria,… compared with sham non‐invasive brain stimulation and/or usual care (low certainty).
1 finding from 1 review
Adverse events: death ‐ at end of treatment (secondary outcome) · people with depression after stroke
It is very uncertain whether psychological therapy changes adverse events: death ‐ at end of treatment (secondary outcome) compared with usual care and/or attention control (very low certainty).
1 finding from 1 review
Adverse events: all ‐ central nervous system events (e.g. suicidal intentions) (secondary outcome) · people with depression after stroke
It is very uncertain whether psychological therapy changes adverse events: all ‐ central nervous system events (e.g. suicidal… compared with usual care and/or attention control (very low certainty).
1 finding from 1 review
Adverse events: all ‐ other events ‐ not listed above (e.g. dysuria, neck pain, eye discomfort) (secondary outcome) · people with depression after stroke
It is very uncertain whether psychological therapy changes adverse events: all ‐ other events ‐ not listed above (e.g. fall,… compared with usual care and/or attention control (very low certainty).
1 finding from 1 review
Adverse events: death ‐ at end of treatment (secondary outcome) · people with depression after stroke
1 finding from 1 review